Argenx's VYVGART Moves Closer To Expanded MG Use As FDA Grants Priority Review

argenx reported that the FDA accepted its supplemental BLA for Priority Review to expand VYVGART (efgartigimod) to adults with AChR-Ab seronegative generalized myasthenia gravis, with a PDUFA date set for May 10, 2026; the filing is supported by Phase 3 ADAPT SERON data showing statistically significant MG-ADL improvements across seronegative subgroups and no new safety signals. VYVGART remains a core commercial driver—preliminary full-year 2025 global product net sales were $4.15 billion, up 90% year-over-year (Q4 sales $1.29 billion)—and approval would establish the drug as the first targeted therapy for this underserved patient population. The news, coupled with recent strong sales and a modest uptick in the stock to $796, is materially positive for argenx but subject to regulatory risk ahead of the 2026 action date.

Analysis

Market structure: Approval for AChR‑Ab seronegative gMG meaningfully expands ARGX’s addressable market and lifts pricing power for VYVGART across rare‑disease neurologic indications; direct winners are ARGX (ARGX) and Halozyme (HALO) via ENHANZE royalties, while hospital‑based IV incumbents and high‑cost chronic IV therapies face share loss and pricing pressure. Expect incremental demand to be concentrated in specialty clinics—ARGX must ramp manufacturing and payer contracting to convert label into revenue; a successful approval could add several hundred million to annual sales over 12–24 months assuming modest penetration (5–15% of unlabeled seronegative pool).

Risks: Tail risks include FDA denial/CRL at PDUFA May 10, 2026, unexpected safety signals in broader seronegative populations, or payor restrictions that cap net price (risk: >20–30% rebate demands). Short term (days–months) the stock is sensitive to headline risk and IV/SC supply updates; long term (quarters–years) adoption depends on diagnostics uptake (MuSK/LRP4 testing rates) and reimbursement policies—hidden dependency: real addressable market hinges on clinician testing behavior and lab access.

Trade implications: Core position: establish a 1–3% portfolio long in ARGX equity and hedge with a Jan 2027 LEAP buy (e.g., synthetic exposure via 800/1000 Jul–Sep 2026 call spread) to cap downside while keeping upside to prior highs (~$935) and beyond. Add a relative‑value trade: long ARGX vs short XBI (equal dollar) to isolate idiosyncratic label upside; consider buying HALO (0.5–1% long) as a leveraged play on ENHANZE royalties. Manage vega: buy call spreads rather than naked calls before PDUFA; trim 50% on a >35% run or on negative FDA signal.

Contrarian angles: Consensus assumes rapid uptake; that may be overstated—diagnostic inertia and payer step therapy could slow monetization, compressing FY2027 revenue by 20–40% versus consensus. Current price already discounts significant approval probability; downside of a CRL could be >30% from $796. Historical parallels (label expansions that required payer negotiation) suggest positive headline → muted long‑term sales unless ARGX secures favorable reimbursement and supply scale within 6–12 months.

Key Decisions for Investors

• Establish a 1–3% portfolio long position in ARGX (ticker ARGX) with a two‑tranche entry: 50% now and 50% 30–60 days before the PDUFA date (May 10, 2026); target sell/trim at +35–50% or on approval with unfavorable rebate language.
• Buy a defined‑risk call spread to express bullish view with limited premium: purchase ARGX Jul/Sep 2026 800/1000 call spread sized to equal 0.5–1% portfolio exposure; this captures post‑PDUFA upside while capping theta loss.
• Construct a relative‑value pair: long ARGX vs short equal‑dollar XBI to hedge sector weakness and isolate idiosyncratic label outcome; rebalance if divergence exceeds 15% in either leg.
• Take a 0.5–1% tactical long in HALO (HALO) to play ENHANZE upside tied to VYVGART SC adoption; exit if gross margin guidance deteriorates or if HALO non‑royalty revenue falls >10% quarter‑over‑quarter.
• Set hard risk triggers: cut all exposure on a CRL or major safety signal; reduce delta‑weighted options by 50% if implied volatility compresses >30% relative to 60‑day average post‑PDUFA; monitor CMS pricing guidance 0–90 days after approval for reimbursement caps.